Cara Therapeutics | CARA - Equity Capital And Reserves


Cara Therapeutics reported $14.5M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Cara Therapeutics USD 14.5M 6.44M Mar/2026
Cassava Sciences USD 68.14M 6.26M Mar/2026
Chugai Pharma JPY 2.03T 135.62B Dec/2025
Cipla INR 344.32B 15.13B Mar/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 95.35M 7.38M Mar/2026
CSL USD 18.66B 2.75B Dec/2025
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
RedHill Biopharma USD 4.27M 8.68M Dec/2025
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025